Journal: Diagnostic Pathology

Article Title: Enhancer of zeste homologue 2 (EZH2) is a reliable immunohistochemical marker to differentiate malignant and benign hepatic tumors

doi: 10.1186/1746-1596-7-86

Figure Lengend Snippet: EZH2 staining

Article Snippet: The primary antibody was a mouse monoclonal anti-EZH2 (clone 11/EZH2) from BD Biosciences (San Jose CA, USA) (dilution 1:100).

Techniques: Expressing, Wilms Tumor Assay

Journal: Diagnostic Pathology

Article Title: Enhancer of zeste homologue 2 (EZH2) is a reliable immunohistochemical marker to differentiate malignant and benign hepatic tumors

doi: 10.1186/1746-1596-7-86

Figure Lengend Snippet: EZH2 staining in primary liver tumors. A/HCC, nuclear staining in tumor cells, the surrounding liver is negative; B/hepatocellular adenoma, there is no staining; C/CCC, note the unstained nuclei of the non tumorous bile duct in the center¸D/positively stained highly differentiated CCC (Klatskin tumour). Scale bar for the Figure 1:50 μm.

Article Snippet: The primary antibody was a mouse monoclonal anti-EZH2 (clone 11/EZH2) from BD Biosciences (San Jose CA, USA) (dilution 1:100).

Techniques: Staining

Journal: International Journal of Oral Science

Article Title: Single-cell transcriptomics reveals cell atlas and identifies cycling tumor cells responsible for recurrence in ameloblastoma

doi: 10.1038/s41368-024-00281-4

Figure Lengend Snippet: Targeting EZH2 inhibits proliferation and stemness in ameloblastoma cells. a Heatmap of the expression of stem cell-associated transcription factors in tumor cells. b Heatmap of the differentiated regulons of each epithelial cluster inferred by SCENIC. c Representative images of colony formation of sorted DiD low AM cells treated with EZH2 siRNAs or EZH2 inhibitors. d , e Quantification of colony numbers of sorted DiD low AM cells treated with EZH2 siRNAs or EZH2 inhibitors, ** P < 0.01 by one-way ANOVA. f Western blot images showing EZH2 expression of DiD low AM cells treated with EZH2 siRNAs. g Representative images showing spheres of sorted DiD low AM cells treated with two EZH2 inhibitors; scale bar, 100 μm. h , i Quantification of sphere number and diameter in sorted DiD low AM cells treated with or without EZH2 inhibitors, *** P < 0.001 by one-way ANOVA. j Representative images showing spheres of sorted DiD low AM cells treated with two different EZH2 siRNAs; scale bar, 100 μm. ( k, l ) Quantification of sphere number and diameter in sorted DiD low AM cells transfected with siRNA control or EZH2 siRNAs, *** P < 0.001 by one-way ANOVA

Article Snippet: The following primary antibodies were used: EZH2 (Cell Signaling Technology, Cat#5246 S; 1:2 000) and GAPDH (Proteintech, 10494-1-AP).

Techniques: Expressing, Western Blot, Transfection, Control

Journal: International Journal of Oral Science

Article Title: Single-cell transcriptomics reveals cell atlas and identifies cycling tumor cells responsible for recurrence in ameloblastoma

doi: 10.1038/s41368-024-00281-4

Figure Lengend Snippet: EZH2 is a novel therapeutic target for ameloblastoma. a KPNN analysis showing top 10 nodes with the most differential weights between primary and recurrent samples. b Representative images of organoids derived from T85 ameloblastoma samples; scale bar, 100 μm (left panel). Immunofluorescent staining showing the expression of PCK and ODAM in ameloblastoma organoids; scale bar, 50 μm (right panel). c , d Representative images and quantification of T85 and T88 ameloblastoma organoids treated with or without EPZ-6438, scale bar, 100 μm, *** P < 0.001 by Student’s t test. e , f Representative images and quantification of T91 and T93 ameloblastoma organoids treated with or without GSK126; scale bar, 100 μm, *** P < 0.001 by Student’s t test. g , h Immunofluorescent staining assay showed KI67 and PCK expression in organoids; scale bar, 50 μm (left panel). The percentage of KI67 expression in organoids with or without EZH2 inhibitors, * P < 0.05 and ** P < 0.01 by Student’s t test (right panel)

Article Snippet: The following primary antibodies were used: EZH2 (Cell Signaling Technology, Cat#5246 S; 1:2 000) and GAPDH (Proteintech, 10494-1-AP).

Techniques: Derivative Assay, Staining, Expressing

Journal: International Journal of Oral Science

Article Title: Single-cell transcriptomics reveals cell atlas and identifies cycling tumor cells responsible for recurrence in ameloblastoma

doi: 10.1038/s41368-024-00281-4

Figure Lengend Snippet: EZH2 expression is increased in recurrent AM and positively correlated with KI67 expression. a Violin plot showing the expression of EZH2 in the five clusters after splitting epithelial cells into primary and recurrent groups. b Representative images of EZH2 IHC staining in primary and recurrent ameloblastoma; scale bar, 100 μm (left panel). Quantification of EZH2 IHC staining in primary and recurrent ameloblastoma, *** P < 0.001 by Student’s t test (right panel). c Representative images of EZH2 IHC staining in unicystic and conventional ameloblastoma; scale bar, 100 μm (left panel). Quantification of EZH2 IHC staining in unicystic and conventional ameloblastoma, *** P < 0.001 by Student’s t test (right panel). d Representative images showing the same region of KI67 and EZH2 IHC staining in serial sections; scale bar, 100 μm (left panel). The correlation analysis between the expression of KI67 and EZH2 was assessed, *** P < 0.001 by Pearson (right panel)

Article Snippet: The following primary antibodies were used: EZH2 (Cell Signaling Technology, Cat#5246 S; 1:2 000) and GAPDH (Proteintech, 10494-1-AP).

Techniques: Expressing, Immunohistochemistry

Journal: Scientific Reports

Article Title: ONECUT2 overexpression promotes RAS-driven lung adenocarcinoma progression

doi: 10.1038/s41598-019-56277-2

Figure Lengend Snippet: ONECUT2 modulates histone methylation through PRC2. ( A ) Western Blot of whole cell lysates from A549-ONECUT2 and A549-E.V. cells using indicated antibodies. The full-length blot is presented in Supplementary Fig. . ( B ) Heatmap of H3K27me3 and EZH2 log 2 fold change signal (A549-ONECUT2 versus ΔDBD) around centers of H3K27me3 loss regions. ( C ) Plot of average EZH2 log 2 fold change by ChIP-Seq (A549-ONECUT2 versus ΔDBD) around activating and repressive ONECUT2 peaks. ( D,E ) GSEA of ONECUT2-activated genes ( D ) and ONECUT2-upregulated genes ( E ) on gene list pre-ranked by log 2 FC after GSK126 treatment. ( F ) GSEA of GSK126 upregulation gene set on gene list pre-ranked based on log 2 FC (KPE versus KP) (Kras G12D/+ ; Trp53 fl/fl ; Eed fl/fl versus Kras G12D/+ ; Trp53 fl/fl ). ( G,H ) GSEA of ONECUT2-activated genes( G ) and ONECUT2-upregulated genes(H) on gene list pre-ranked by log 2 FC (KPE versus KE).

Article Snippet: Primary antibodies against EZH2 (5346 S, Cell Signaling), SUZ12 (3737 S, Cell Signaling), EED (05-1320, Millipore), HA (2367 S, Cell Signaling), GAPDH (G8795, Sigma) and α-tubulin (T5168, Sigma) were used in the study.

Techniques: Methylation, Western Blot, ChIP-sequencing